Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil 32 mg and Hydrochlorothiazide 25 mg in Comparison with Candesartan Cilexetil 32 mg, Hydrochlorothiazide 25 mg and Placebo in Hypertensive Adults
1.To compare sitting DBP lowering effect of candesartan cilexetil (candesartan)/hydrochlorothiazide (HCT) 32/25 mg with that of candesartan 32 mg. 2. To compare sitting Systolic Blood Pressure (SBP) l...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A randomized, double-blind, double-dummy, two-way cross-over study evaluating systemic bioavailability and airway clearance of Symbicort® Turbuhaler® 320/9μg/inhalation versus Seretide™ Diskus ™50/500μg/inhalation after single inhalations in patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers
The primary objective is to evaluate airway tissue availability of budesonide via Symbicort Turbuhaler and fluticasone via Seretide Diskus in severe COPD patients and healthy volunteers, using area un...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A phase II, open label, multiarm study to assess the efficay of new drugs in patients with Small Cell Lung Cancer whose cancer worsened during or after 90 days of platinum based chemotherapy Ensayo fase II, abierto, multi-brazo para determinar la eficacia de nuevos medicamentos en pacientes con cáncer de pulmón de células pequeñas cuyo cáncer empeorado durante o después de 90 días de quimioterapia basada en platino
To assess the preliminary efficacy of each treatment arm in terms of Overall Response Rate. ORR will be evaluated using Investigator assessments according to RECIST 1.1 Evaluar la eficacia preli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca Sverige
MAJ Il y a 5 ans
A 52-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered to Patients with Type 2 Diabetes
Is to assess whether tesaglitazar given as monotherapy is non-inferior to glibenclamide given as monotherapy during 52 weeks in improving glycaemic control in patients with type 2 diabetes as determin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
FAST – A randomised, open-label, parallel, multicentre Phase IIIb Study to evaluate the Efficacy and Safety of Quetiapine IR titrared over 4 Days in Patients with Acute Psychosis (Rapid versus Conventional Titration)
The main objective is to compare the efficacy of quetiapine IR in patients with acute schizophrenia, schizoaffective disorder, psychosis NOS or bipolar mania with psychotic symptoms, following rapid t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236 as an Oral Tablet in Patients with Moderate to Severe COPD
To investigate the tolerability and safety of AZD1236, as an oral tablet, in COPD patients by assessment of: incidence and nature of adverse events vital signs and laboratory safety assessments
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca K.K
MAJ Il y a 5 ans
A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children age 7 years through 18 years
To assess the efficacy (the incidence of laboratory-confirmed influenza infection caused by any community-acquired wild-type strains matched to the vaccine) of MEDI3250 compared to placebo. To asses...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A single-dose study to investigate the effects of 3 different doses of inhaled AZD2115 in COPD patients
To investigate the local bronchodilatory effects of 3 different doses of AZD2115 compared with placebo, with respect to peak and trough forced expiratory volume in the first second (FEV1), in patients...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
This is a randomized, placebo-controlled, double−blind study meaning neither the patient nor the study doctor will know which medication is being given. The study is randomized, meaning that participants will be randomly assigned to 1 of 3 treatment groups. To evaluate the efficacy, how the drug is absorbed in the blood stream and how safe is the study drug called AZD8871 when this is administered once daily during two weeks in patients with moderate to severe COPD
To evaluate the efficacy of inhaled AZD8871 in patients with moderate to severe COPD patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca Sweden
MAJ Il y a 5 ans
A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort® Turbuhaler® 160/4.5 µg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort® Turbuhaler® 320/9 µg/inhalation b.i.d. + one inhalation of Pulmicort® Turbuhaler® 400 µg/dose b.i.d. plus Terbutaline Turbuhaler® 0.4 mg/inhalation as-needed. A 12-month, randomised, double-blind, parallel-group, active controlled, multinational, phase III B study in adult patients with asthma
The main objective of the trial is to compare the anti-inflammatory effects of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 µg/inhalation b.i.d. plus as-needed) versus a fixed dose...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
11
12
13
14
15
16
17
18
19
20
Suivant